Reporting for the family-office world.

Join the Family Office Networks’ Webinar Series featuring Hemptown USA. Eric Gripentrog, CEO will discuss hemp derived cannabinoids, including CBD and CBG, and the platform that Hemptown USA has built for industry consolidation and integration. Hemptown is a leader in cultivation with a Fortune 500 management team, including Kelloggs and Intel. It is one of the largest producers of CBG globally.

Join the Family Office Networks’ Webinar Series featuring Bunkport Partners LP. Bunkport Partners LP is a US equity focused opportunistic investment strategy designed to deliver superior performance, through meaningfully participating in the market’s strongest stocks, while also avoiding the severe equity market drawdowns. They have a 20% annual net return target with a low correlation to the major equity markets or any specific investment style. Bunkport endeavors to generate a private equity return profile with a public equity liquidity profile.

Join the Family Office Networks’ Webinar Series featuring Psy Therapeutics, Inc. Psy Therapeutics, Inc. is an emerging biopharmaceutical company focused on developing transformative medicines to treat serious neuropsychiatric disorders. The Company’s novel approach to customized small molecule drug discovery and development combines cutting-edge technology with an extensive network of collaborators to drive R&D innovation and productivity. Mental illness and neurodegenerative disorders continue to wreak havoc on patients, their families, and our society. Introduction: tZERO Overview Presentation Led by tZERO’s Business Development & Capital Markets Team Panel Discussion: ‘Advantages of Enabling Liquidity of Private Assets’ Discussion with Panelists: Michael Gaviser, Former KKR Managing Director Alan Konevsky, tZERO Chief Legal Officer Hubertus Thonhauser, Tezos Foundation Council Chair Member Keynote Presentation: ‘The Future of Investments & Trading’ Keynote Led by John Jacobs, Former Nasdaq EVP  Join the Family Office Networks’ Webinar Series to learn more about tZERO, a leader in financial innovation and liquidity for private companies. tZERO Group, Inc. and its broker-dealer subsidiaries (tZERO) offers institutional-grade solutions for issuers looking to digitize their capital table and trade on a regulated alternative trading system. tZERO democratizes access to private assets by providing a simple, automated, and efficient trading venue to broker-dealers, institutions, and investors. TRAC is a new kind of quantitative early-stage venture firm. The unique predictive technology combines superhuman forecasters and machine intelligence to accurately predict future unicorns early and with an overall accuracy 60%.

Join the Family Office Networks’ Webinar Series to learn more about tZERO, a leader in financial innovation and liquidity for private companies. The webinar will include the following: Introduction: tZERO Overview Presentation Led by tZERO’s Business Development & Capital Markets Team Panel Discussion: ‘Advantages of Enabling Liquidity of Private Assets’ Discussion with Panelists: Michael Gaviser, Former KKR Managing Director Alan Konevsky, tZERO Chief Legal Officer Hubertus Thonhauser, Tezos Foundation Council Chair Member Keynote Presentation: ‘The Future of Investments & Trading’ Keynote Led by John Jacobs, Former Nasdaq EVP  Join the Family Office Networks’ Webinar Series to learn more about tZERO, a leader in financial innovation and liquidity for private companies. tZERO Group, Inc. and its broker-dealer subsidiaries (tZERO) offers institutional-grade solutions for issuers looking to digitize their capital table and trade on a regulated alternative trading system. tZERO democratizes access to private assets by providing a simple, automated, and efficient trading venue to broker-dealers, institutions, and investors. TRAC is a new kind of quantitative early-stage venture firm. The unique predictive technology combines superhuman forecasters and machine intelligence to accurately predict future unicorns early and with an overall accuracy 60%.

Join the Family Office Networks Webinar Series Featuring Trac Unicorn Fund “A Quantitative Venture Firm Investing in Future Unicorns”. TRAC is a new kind of quantitative early-stage venture firm. The unique predictive technology combines superhuman forecasters and machine intelligence to accurately predict future unicorns early and with an overall accuracy 60%.

Join the Family Office Networks Webinar Series Featuring Innovative Medicine Partners (IMP). Innovative Medicine Partners (IMP) is a dynamic network of medical visionaries working in collaboration to develop novel medical procedures and devices. Our expert team of clinicians, scientists, engineers, legal advisors, regulatory specialists, marketing experts, and financial professionals possesses an unparalleled level of experience in all aspects required to bring medical devices from concept to commercialization.

Emerald Park Capital (EPC) is an emerging manager actively providing capital to the legal cannabis industry – Currently raising flagship fund of up to $110 million. Current market factors combined with positive industry dynamics present investors with excellent investment opportunities and risk adjusted returns Despite COVID-19, the cannabis industry has been deemed essential and continues to grow Typical investments include senior secured debt facilities and structured equity –Utilizing a combination of current yield and equity kickers – Strong enterprise level credit support provided by top tier borrowers EPC has built a team of seasoned investors and partners who have worked together on numerous deals over the past 10+ years, with a combined cannabis experience of 60+ completed transactions – Infrastructure support provided by EPC’s affiliate, Bryant Park Capital, a middle market investment bank that has advised in >300 closed transactions, representing >$30 billion in value

Come join the Family Office Networks’ Webinar Series featuring AltaThera Pharmaceuticals. AltaThera Pharmaceuticals is a commercial stage hospital-focused pharmaceutical company applying innovative science to address unmet medical needs while reducing healthcare costs. AltaThera is committed to providing therapies that increase efficient treatment of the complex challenges of atrial fibrillation (AFib), a serious and costly health problem.